Hyperprolactinemia during antipsychotics treatment increases the level of coagulation markers

Neuropsychiatric Disease and Treatment

Volumn 11, Issue , 2015, Pages 477-484

  Ishioka, Masamichi ^a   Yasui Furukori, Norio ^a   Sugawara, Norio ^a   Furukori, Hanako ^a   Kudo, Shuhei ^a   Nakamura, Kazuhiko ^a  

^a HIROSAKI UNIVERSITY   (Japan)

Author keywords

Antipsychotics; Prolactin; Venous thromboembolism

Indexed keywords

BIOLOGICAL MARKER; D DIMER; FIBRIN; FIBRINOGEN DEGRADATION PRODUCT; NEUROLEPTIC AGENT; PROLACTIN; THROMBIN ANTITHROMBIN COMPLEX;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERPROLACTINEMIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; SCHIZOPHRENIA; SEX DIFFERENCE; TREATMENT DURATION; VENOUS THROMBOEMBOLISM;

EID: 84923358445     PISSN: None     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S75176     Document Type: Article

References (43)

1. Kyrle PA, Eichinger S. Deep vein thrombosis. Lancet. 2005;365: 1163–1174.
2. Ageno W, Squizzato A, Garcia D, Imberti D. Epidemiology and risk factor of venous thromboembolism. Semin Thromb Hemost. 2006;32(7): 651–658.
3. Anderson FA Jr, Spencer FA. Risk factors for venous thromboembolism. Circulation. 2003;107(23 Suppl 1):9–16.
4. Laursen SB, Jensen TN, Bolwig T, Olsen NV. Deep venous throbosis and pulmonary embolism following physical restraint. Acta Psychiatr Scand. 2005;111(4):324–327.
5. Lachner C, Sandson NB. Medical complications of catatonia: a case of catatonia-induced deep venous thrombosis. Psychosomatics. 2003; 44(6):512–514.
6. Addonizio G, Susman VL, Roth SD. Neuroleptic malignant syn­drome: review and analysis of 115 cases. Biol Psychiatry. 1987;22(8): 1004–1020.
7. Hägg S, Spigset O. Antipsychotic-induced venous thromboembolism: a review of the evidence. CNS Drugs. 2002;16(11):765–776.
8. Zornberg GL, Jick H. Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case-control study. Lancet. 2000;356(9237):1219–1223.
9. Parkin L, Skegg DC, Herbison GP, Paul C. Psychotropic drugs and fatal pulmonary embolism. Pharmacoepidemiol Drug Saf. 2003;12(8): 647–652.
10. Lacut K, Le Gal G, Couturaud F, et al. Association between antip­sychotic drugs, antidepressant drugs and venous thromboembolism: results from the EDITH case-control study. Fundam Clin Pharmacol. 2007;21(6):643–650.
11. Ray JG, Mamdani MM, Yeo EL. Antipsychotic and antidepressant drug use in the elderly and the risk of venous thromboembolism. Thromb Haemost. 2002;88(2):205–209.
12. Jönsson AK, Horváth-Puhó E, Hägg S, Pedersen L, Sørensen HT. Antipsychotics and risk of venous thromboembolism: a population-based case-control study. Clin Epidemiol. 2009;1:19–26.
13. Hamanaka S, Kamijo Y, Nagai T, et al. Massive pulmonary throm­boembolism demonstrated at necropsy in Japanese psychiatric patients treated with neuroleptics including atypical antipsychotics. Circ J. 2004; 68(9):850–852.
14. Liperoti R, Pedone C, Lapane KL, et al. Venous thromboembolism among elderly patients treated with atypical and conventional antipsy­chotic agents. Arch Intern Med. 2005;165(22):2677–2682.
15. Thomassen R, Vandenbroucke JP, Rosendaal FR. Antipsychotic medi­cation and venous thrombosis. Br J Psychiatry. 2001;179:63–66.
16. Kleijer BC, Heerdink ER, Egberts TC, et al. Antipsychotic drug use and the risk of venous thromboembolism in elderly patients. J Clin Psychopharmacol. 2010;30(5):526–530.
17. Chris P, Carol C, Julia H. Antipsychotic drugs and risk of venous throm­boembolism: nested case-contorol study. BMJ. 2010;341:c4245.
18. Shulman M, Jennifer N, Manu N. Thrombotic complications of treat­ment with antipsychotics drugs. Minerva Med. 2013;104:175–184.
19. Heida NM, Schäfer K, Konstantinides S. Prolactin as a modulator of platelet function and thrombosis: the end of the story, or a new begin­ning? Thromb Haemost. 2009;101(6):991–992.
20. Horrobin DF, McNeilly AS, Jackson FS, et al. Letter: prolactin and myocardial infarction. Lancet. 1973;2(7840):1261.
21. Raaz D, Wallaschofski H, Stumpf C, et al. Increased prolactin in acute coronary syndromes as putative Co-activator of ADP-stimulated P-selectin expression. Horm Metab Res. 2006;38(11):767–772.
22. Byerly M, Suppes T, Tran QV, et al. Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and cur­rent perspectives. J Clin Psychopharmacol. 2007;27(6):639–661.
23. Bostwick JR, Guthrie SK, Ellingrod VL. Antipsychotic-induced hyper­prolactinemia. Pharmacotherapy. 2009;29(1):64–73.
24. Meaney AM, Smith S, Howes OD, et al. Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br J Psychiatry. 2004;184:503–508.
25. Yavuz D, Deyneli O, Akpinar I, et al. Endothelial function, insulin sensi­tivity and inflammatory markers in hyperprolactinemic pre-menopausal women. Eur J Endocrinol. 2003;149(3):187–193.
26. Urban A, Masopust J, Malý R, et al. Prolactin as a factor for increased platelet aggregation. Neuro Endocrinol Lett. 2007;28(4):518–523.
27. Erem C, Kocak M, Nuhoglu I, et al. Blood coagulation, fibrinolysis and lipid profile in patients with prolactinoma. Clin Endocrinol (Oxf). 2010;73(4):502–507.
28. Anaforoglu I, Ertorer ME, Kozanoglu I, et al. Macroprolactinemia, like hyperprolactinemia, may promote platelet activation. Endocrine. 2010; 37(2):294–300.
29. Skokou M, Gourzis P. Pulmonary embolism related to amisulpride treatment: a case report. Case Rep Psychiatry. 2013;718950.
30. Kurrelmeyer K, Becker L, Becker D, et al. Platelet hyperreactivity in women from families with premature atherosclerosis. J Am Med Womens Assoc. 2003;58(4):272–277.
31. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and toler­ability of 15 antipsychotic drugs in schizophrenia: a multipletreatments meta-analysis. Lancet. 2013;382(9896):951–962.
32. Yasui-Furukori N, Furukori H, Sugawara N et al. Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia. J Clin Psychopharmacol. 2010;30(5):596–599.
33. Peuskens J, Pani L, Detraux J, et al. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs. 2014;28(5):421–453.
34. Faraday N, Goldschmidt-Clermont PJ, Bray PF. Gender differences in platelet GPIIb-IIIa activation. Thromb Haemost. 1997;77(4): 748–754.
35. Becker DM, Segal J, Vaidya D, et al. Sex differences in platelet reac­tivity and response to low-dose aspirin therapy. JAMA. 2006;295(12): 1420–1427.
36. Kluft C, Lansink M. Effect of oral contraceptives on haemostasis variables. Thromb Haemost. 1997;78(1):315–326.
37. Majumdar A, Mangal NS. Hyperprolactinemia. J Hum Reprod Sci. 2013;6(3):168–175.
38. Woodward M, Lowe GD, Rumley A, et al. Epidemiology of coagulation factors, inhibitors and activation markers: the Third Glasgow MONICA Survey. II. Relationships to cardiovascular risk factors and prevalent cardiovascular disease. Br J Haematol. 1997;97(4):785–797.
39. Omote M, Asakura H, Takamichi S, et al. Changes in molecular markers of hemostatic and fibrinolytic activation under various sampling condi­tions using vacuum tube samples from healthy volunteers. Thromb Res. 2008;123(2):390–395.
40. Lowe GD. Virchow’s triad revisited: abnormal flow. Pathophysiol Haemost Thromb. 2003;33(5–6):455–457.
41. Liperoti R, Gambassi G. Antipsychotics and the risk of venous throm­boembolism. BMJ. 2010;341:c4216.
42. Dunn EJ, Grant PJ. Type 2 diabetes: an atherothrombotic syndrome. Curr Mol Med. 2005;5(3):323–332.
43. Beckman MG, Hooper C, Critchley SE, et al. Venous thromboembolism: a public health concern. Am J Prev Med. 2010;38(4 Suppl): S495–S501.